Respiratory syncytial virus (RSV) is a leading cause of infant morbidity. France has implemented a national campaign using nirsevimab to prevent RSV-related infections in infants. This study assessed its effectiveness in preventing hospitalization due to bronchiolitis in emergency department (ED). This retrospective study was conducted among six pediatric EDs in the Greater Paris area, France, and included infants aged
Auteur : Marouk Alexis, Verrat Bernadette, Pontais Isabelle, Cojocaru Dumitru, Chappuy Hélène, Craiu Irina, Quagliaro Pauline, Gajdos Vincent, Soussan-Banini Valérie, Gallien Yves, Feral-Pierssens Anne-Laure
European journal of pediatrics, 2025, vol. 184, n°. 3, p. 229
